Developer docs
API playgroundTry for free, no card

Search company profiles

Mapmygenome

Full company profile

uuid0008uzj

Namestring
Mapmygenome
Legal namestring
Mapmygenome India
Websiteurl
mapmygenome.in
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Mapmygenome is an India-headquartered molecular diagnostics company founded in 2013 (per company history; firmographics lists 2012) and based in Hyderabad, operating with 11-50 employees. It provides direct-to-consumer at-home DNA testing kits and clinical-grade diagnostic genomic services through a multi-omics platform that integrates DNA sequencing, epigenetics, and gut microbiome metagenomics. Core products include Genomepatri (polygenic risk score-based wellness planning), MapmyBiome (shotgun-sequenced gut microbiome analysis), MedicaMap (pharmacogenomics across 165+ medications), MapmyEpigenome (biological age via DNA methylation), and MapmySpark (mitochondrial wellness and maternal ancestry). Clinical offerings include Whole Exome Sequencing, Whole Genome Sequencing at 30x coverage, NIPT, and Hereditary Cancer Panels sold through a separate doctor-prescribed channel.

The company operates NABL and CAP dual-accredited laboratories in India and acquired Canada's Microbiome Insights in May 2025 to establish North American operations. Business model is predominantly transactional DTC e-commerce (one-time kit purchases priced Rs. 6,999 to Rs. 200,000), augmented by clinical diagnostic sales through healthcare providers and a premium bundle strategy (Stay Young, Live Long, Ultimate Biohacking). All tests include genetic counseling and the platform accepts raw data uploads from 9 competitor services including 23andMe and Ancestry. Key differentiators are India-specific PRS calibration and a proprietary 20,000+ record Indian subpopulation ancestry database, addressing underrepresentation of South Asian genomes in global datasets. Compliance posture spans ISO 15189, ISO 27001, ISO 20000-1, HIPAA, GDPR, and DPDP.

Short descriptiontext

Mapmygenome is a Hyderabad-based molecular diagnostics company offering at-home DNA testing kits and clinical genomic services through CAP and NABL accredited labs, serving health-conscious consumers, clinicians, and reproductive health markets across India and, since May 2025, North America via its Microbiome Insights subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, genomic testing services, DNA testing kits, pharmacogenomic testing, microbiome analysis
Industry6 codes
1Molecular Diagnostics & Genomics Laboratories
CodeHLAFAMAEPrimaryYes
2Genetic, Cytogenetic & Prenatal Screening IVD
CodeHLAHAAAIPrimaryNo
3Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
CodeHLAAALADPrimaryNo
4Genetic & Prenatal Testing Laboratories
CodeHLAFAMAHPrimaryNo
5Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
CodeHLAAALAJPrimaryNo
6Molecular Diagnostics (PCR/qPCR, NGS-based assays)
CodeHLAAALAAPrimaryNo
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomic Testing Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1At-Home DNA Testing Kits
TypeOne Time License
Description

One-time purchase of DNA testing kits with analysis and digital report delivery. Includes genetic counseling session. Products include Genomepatri, MapmyBiome, MedicaMap, MapmyEpigenome, and specialized tests.

mapmygenome.in
2Premium Bundles and Programs
TypeOne Time License
Description

Bundled product packages combining multiple tests (Stay Young, Ultimate Biohacking, Live Long) at discounted rates versus individual purchases

mapmygenome.in
3Diagnostic Genomic Tests
TypeOne Time License
Description

Clinical-grade diagnostic tests including Whole Exome Sequencing, Whole Genome Sequencing, Hereditary Cancer Panels, and NIPT sold through doctor-prescribed channel

mapmygenome.in
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details12 tiers
1Genomepatri - Core DNA wellness test covering traits, nutrition, disease risk, and drug response
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 7,999.00

mapmygenome.in
2MapmyBiome - Gut microbiome test with shotgun sequencing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 14,999.00 (currently offering Rs 5000 discount)

mapmygenome.in
3MedicaMap - Pharmacogenomic drug response test covering 165+ medications
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 6,999.00

mapmygenome.in
4MapmyEpigenome - Biological age and aging analysis
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 85,000.00

mapmygenome.in
5Whole Exome Sequencing - Comprehensive clinical genetic analysis
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 26,000.00

mapmygenome.in
6Whole Genome Sequencing - Complete genome analysis at 30x coverage
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 89,000-99,000

mapmygenome.in
7NIPT - Non-Invasive Prenatal Testing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 15,000.00

mapmygenome.in
8Hereditary Cancer Panel - Cancer risk DNA test
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 25,000.00

mapmygenome.in
9MapmySpark - Mitochondrial wellness and heritage report
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 9,999.00

10MatchmyGenome - Couple carrier screening
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 50,000.00

mapmygenome.in
11Ultimate Biohacking Package Phase I - Foundational multi-omics testing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 200,000.00

mapmygenome.in
12Live Long Bundle - Genetics, Microbiome, Epigenetics combined
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Rs. 122,997.00

mapmygenome.in
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 9 records shown
1Genomepatri
Description

DNA-based wellness planner that provides personalized health risk assessment, nutrition and fitness insights, disease risk prediction, and medication response analysis

mapmygenome.in
+8 more records
Core offering1 text field

Mapmygenome offers direct-to-consumer at-home DNA testing kits (e.g., Genomepatri, MapmyBiome) and clinical diagnostic genomic tests (e.g., NIPT, Hereditary Cancer Panel, Whole Exome/Genome Sequencing) ordered through healthcare providers. The company provides end-to-end services including sample collection, multi-omics analysis (genomics, microbiome, epigenomics), polygenic risk score reporting, and genetic counseling.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 100,000 genomes interpreted by team
+1 more record
Product overview1 text field

Mapmygenome is a multi-omics genomics company offering a comprehensive portfolio of at-home DNA testing products and clinical diagnostic services. The core product line includes Genomepatri (DNA-based wellness planner), MapmyBiome (gut microbiome analysis), MedicaMap (pharmacogenomics), and MapmyEpigenome (biological age testing). These are complemented by specialized products including ancestry analysis (Genomepatri Heritage), mitochondrial wellness (MapmySpark), fitness nutrition (Myfitgene), and beauty (Beautymap). For clinical diagnostics, the company provides Whole Exome Sequencing, Whole Genome Sequencing, Hereditary Cancer Panel, NIPT prenatal testing, Cardiomap, and MatchmyGenome carrier screening. Premium bundled offerings like the Ultimate Biohacking Package Phase I combine multiple testing modalities (genomic, microbiome, epigenomic) into unified health optimization programs. The company operates CAP and NABL accredited laboratories and has expanded internationally through acquisition of Microbiome Insights (Canada).

Product and service20 records
1Genomepatri
CategoryConsumer DNA Testing
2Genomepatri Heritage
CategoryConsumer DNA Testing
3MapmyBiome
CategoryConsumer DNA Testing
4MedicaMap
CategoryClinical Diagnostics
5MapmyEpigenome Advanced
CategoryConsumer DNA Testing
6MapmySpark
CategoryConsumer DNA Testing
7Whole Exome Sequencing
CategoryClinical Diagnostics
8Whole Genome Sequencing
CategoryClinical Diagnostics
9Hereditary Cancer Panel
CategoryClinical Diagnostics
10Non-Invasive Prenatal Testing (NIPT)
CategoryClinical Diagnostics
11Cardiomap
CategoryConsumer DNA Testing
12Beautymap
CategoryConsumer DNA Testing
13Myfitgene
CategoryConsumer DNA Testing
14MatchmyGenome
CategoryConsumer DNA Testing
15Ultimate Biohacking Package Phase I
CategoryConsumer DNA Testing
16Stay Young Bundle
CategoryConsumer DNA Testing
17Stay Informed Bundle
CategoryConsumer DNA Testing
18Discover Yourself Bundle
CategoryConsumer DNA Testing
19Look Better Bundle
CategoryConsumer DNA Testing
20Live Long Bundle
CategoryConsumer DNA Testing
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Microbiome Insights
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Acquired Canadian microbial sequencing company Microbiome Insights in May 2025 to gain access to CAP-accredited laboratory and expand into the US market. The acquisition enhances microbiome testing services for North America by leveraging Microbiome Insights' expertise in microbial genomics and positions Mapmygenome as a leader in microbiome health and integrated genomics services.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Color Genomics
TypeEmerging player
Description

US clinical genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic tests through employers and providers. Comparable to Mapmygenome's clinical channel (Hereditary Cancer Panel, MedicaMap) via a B2B2C distribution model.

2MyHeritage
TypeBroad incumbent
Description

Global genealogy and DNA testing platform with strong ancestry and family-tree focus. Mapmygenome accepts raw data uploads from MyHeritage and competes for the ancestry-driven segment through Genomepatri Heritage.

3Nebula Genomics
TypeEmerging player
Description

US-based DTC whole-genome sequencing company offering deep-coverage sequencing at consumer price points. Comparable to Mapmygenome's Whole Genome Sequencing product for the international tech-savvy customer base.

4Prenetics
TypeRegional player
Description

Hong Kong-listed genomics and preventive health company offering DNA testing, NIPT, and consumer health products across Asia. Regional competitor with comparable multi-omics ambitions and a Hong Kong/SEA geographic focus.

5Circle DNA
TypeRegional player
Description

Asia-focused (Hong Kong) premium genetic testing brand offering whole genome sequencing and health reports. Operates in the same premium-APAC wellness segment as Mapmygenome's international storefront but is primarily Greater China/Southeast Asia focused.

6MedGenome
TypeDirect peer
Description

India-headquartered genomics and molecular diagnostics company offering genetic testing, NIPT, hereditary cancer panels, and clinical interpretation. Direct competitor in the Indian genetic diagnostics market across both DTC and clinical channels.

7Strand Life Sciences
TypeDirect peer
Description

India-based clinical genomics and bioinformatics company providing genetic testing, NIPT, prenatal screening, and oncology panels. Competes head-to-head with Mapmygenome in India for clinical genomic testing services.

8Xcode Life
TypeDirect peer
Description

Chennai-based DTC genetic testing company focused on South Asian consumers, offering nutrigenomics, fitness, and ancestry tests. Direct competitor in the Indian DTC wellness genomics niche with overlapping product positioning.

923andMe
TypeBroad incumbent
Description

Largest global DTC genetic testing company offering ancestry and health predisposition reports. Mapmygenome accepts raw data uploads from 23andMe and competes for the same Indian wellness customer, though 23andMe lacks India-specific PRS calibration.

10Ancestry
TypeBroad incumbent
Description

Global leader in ancestry DNA testing with the largest consumer genetic database. Mapmygenome competes for ancestry-driven Indian customers through Genomepatri Heritage, where its India-specific subpopulation database is a key differentiator.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mapmygenome

Genomic Testing Servicesmapmygenome.in

Mapmygenome is a Hyderabad-based molecular diagnostics company offering at-home DNA testing kits and clinical genomic services through CAP and NABL accredited labs, serving health-conscious consumers, clinicians, and reproductive health markets across India and, since May 2025, North America via its Microbiome Insights subsidiary.

What Mapmygenome does

Mapmygenome is an India-headquartered molecular diagnostics company founded in 2013 (per company history; firmographics lists 2012) and based in Hyderabad, operating with 11-50 employees. It provides direct-to-consumer at-home DNA testing kits and clinical-grade diagnostic genomic services through a multi-omics platform that integrates DNA sequencing, epigenetics, and gut microbiome metagenomics. Core products include Genomepatri (polygenic risk score-based wellness planning), MapmyBiome (shotgun-sequenced gut microbiome analysis), MedicaMap (pharmacogenomics across 165+ medications), MapmyEpigenome (biological age via DNA methylation), and MapmySpark (mitochondrial wellness and maternal ancestry). Clinical offerings include Whole Exome Sequencing, Whole Genome Sequencing at 30x coverage, NIPT, and Hereditary Cancer Panels sold through a separate doctor-prescribed channel.

The company operates NABL and CAP dual-accredited laboratories in India and acquired Canada's Microbiome Insights in May 2025 to establish North American operations. Business model is predominantly transactional DTC e-commerce (one-time kit purchases priced Rs. 6,999 to Rs. 200,000), augmented by clinical diagnostic sales through healthcare providers and a premium bundle strategy (Stay Young, Live Long, Ultimate Biohacking). All tests include genetic counseling and the platform accepts raw data uploads from 9 competitor services including 23andMe and Ancestry. Key differentiators are India-specific PRS calibration and a proprietary 20,000+ record Indian subpopulation ancestry database, addressing underrepresentation of South Asian genomes in global datasets. Compliance posture spans ISO 15189, ISO 27001, ISO 20000-1, HIPAA, GDPR, and DPDP.

Mapmygenome firmographics

Firmographics
Name
Mapmygenome
Legal name
Mapmygenome India
Website
https://mapmygenome.in
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Mapmygenome is a Hyderabad-based molecular diagnostics company offering at-home DNA testing kits and clinical genomic services through CAP and NABL accredited labs, serving health-conscious consumers, clinicians, and reproductive health markets across India and, since May 2025, North America via its Microbiome Insights subsidiary.
Ownership category
akta.pro rank

Mapmygenome industry classification

Industry
Product category
Genomic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
akta.pro secondary industries
Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

  • Molecular diagnostics
  • Genomic testing services
  • DNA testing kits
  • Pharmacogenomic testing
  • Microbiome analysis

Where Mapmygenome is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices3 records

Markets served

Mapmygenome business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. At-Home DNA Testing Kits: One-time purchase of DNA testing kits with analysis and digital report delivery. Includes genetic counseling session. Products include Genomepatri, MapmyBiome, MedicaMap, MapmyEpigenome, and specialized tests.
  2. Premium Bundles and Programs: Bundled product packages combining multiple tests (Stay Young, Ultimate Biohacking, Live Long) at discounted rates versus individual purchases
  3. Diagnostic Genomic Tests: Clinical-grade diagnostic tests including Whole Exome Sequencing, Whole Genome Sequencing, Hereditary Cancer Panels, and NIPT sold through doctor-prescribed channel

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goGenomepatri - Core DNA wellness test covering traits, nutrition, disease risk, and drug response
One time/ perpetual licensePay-as-you-goMapmyBiome - Gut microbiome test with shotgun sequencing
One time/ perpetual licensePay-as-you-goMedicaMap - Pharmacogenomic drug response test covering 165+ medications
One time/ perpetual licensePay-as-you-goMapmyEpigenome - Biological age and aging analysis
One time/ perpetual licensePay-as-you-goWhole Exome Sequencing - Comprehensive clinical genetic analysis
One time/ perpetual licensePay-as-you-goWhole Genome Sequencing - Complete genome analysis at 30x coverage
One time/ perpetual licensePay-as-you-goNIPT - Non-Invasive Prenatal Testing
One time/ perpetual licensePay-as-you-goHereditary Cancer Panel - Cancer risk DNA test
One time/ perpetual licensePay-as-you-goMapmySpark - Mitochondrial wellness and heritage report
One time/ perpetual licensePay-as-you-goMatchmyGenome - Couple carrier screening
One time/ perpetual licensePay-as-you-goUltimate Biohacking Package Phase I - Foundational multi-omics testing
One time/ perpetual licensePay-as-you-goLive Long Bundle - Genetics, Microbiome, Epigenetics combined

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Mapmygenome product offering

Product offering

Core offering

Mapmygenome offers direct-to-consumer at-home DNA testing kits (e.g., Genomepatri, MapmyBiome) and clinical diagnostic genomic tests (e.g., NIPT, Hereditary Cancer Panel, Whole Exome/Genome Sequencing) ordered through healthcare providers. The company provides end-to-end services including sample collection, multi-omics analysis (genomics, microbiome, epigenomics), polygenic risk score reporting, and genetic counseling.

Product overview

Mapmygenome is a multi-omics genomics company offering a comprehensive portfolio of at-home DNA testing products and clinical diagnostic services. The core product line includes Genomepatri (DNA-based wellness planner), MapmyBiome (gut microbiome analysis), MedicaMap (pharmacogenomics), and MapmyEpigenome (biological age testing). These are complemented by specialized products including ancestry analysis (Genomepatri Heritage), mitochondrial wellness (MapmySpark), fitness nutrition (Myfitgene), and beauty (Beautymap). For clinical diagnostics, the company provides Whole Exome Sequencing, Whole Genome Sequencing, Hereditary Cancer Panel, NIPT prenatal testing, Cardiomap, and MatchmyGenome carrier screening. Premium bundled offerings like the Ultimate Biohacking Package Phase I combine multiple testing modalities (genomic, microbiome, epigenomic) into unified health optimization programs. The company operates CAP and NABL accredited laboratories and has expanded internationally through acquisition of Microbiome Insights (Canada).

Differentiator

Problem solved

Functional benefit

Brands

  • Genomepatri: DNA-based wellness planner that provides personalized health risk assessment, nutrition and fitness insights, disease risk prediction, and medication response analysis
  • MapmyBiome
  • MedicaMap
  • MapmyEpigenome
  • MapmySpark
  • Myfitgene
  • Beautymap
  • Cardiomap
  • Microbiome Insights

Products and services

  • Genomepatri
  • Genomepatri Heritage
  • MapmyBiome
  • MedicaMap
  • MapmyEpigenome Advanced
  • MapmySpark
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • Hereditary Cancer Panel
  • Non-Invasive Prenatal Testing (NIPT)
  • Cardiomap
  • Beautymap
  • Myfitgene
  • MatchmyGenome
  • Ultimate Biohacking Package Phase I
  • Stay Young Bundle
  • Stay Informed Bundle
  • Discover Yourself Bundle
  • Look Better Bundle
  • Live Long Bundle

Quantifiable outcome

  • Over 100,000 genomes interpreted by team
  • +1 more outcomes

Companies that use Mapmygenome

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Mapmygenome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability4 records

Feature7 records

Mapmygenome partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Microbiome InsightscoreStrategic or Co-development Partner · 1 May 2025Acquired Canadian microbial sequencing company Microbiome Insights in May 2025 to gain access to CAP-accredited laboratory and expand into the US market. The acquisition enhances microbiome testing services for North America by leveraging Microbiome Insights' expertise in microbial genomics and positions Mapmygenome as a leader in microbiome health and integrated genomics services.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Mapmygenome competitors and assessment

Company assessment

Emerging players

  • Color Genomics: US clinical genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic tests through employers and providers. Comparable to Mapmygenome's clinical channel (Hereditary Cancer Panel, MedicaMap) via a B2B2C distribution model.
  • Nebula Genomics: US-based DTC whole-genome sequencing company offering deep-coverage sequencing at consumer price points. Comparable to Mapmygenome's Whole Genome Sequencing product for the international tech-savvy customer base.

Broad incumbents

  • MyHeritage: Global genealogy and DNA testing platform with strong ancestry and family-tree focus. Mapmygenome accepts raw data uploads from MyHeritage and competes for the ancestry-driven segment through Genomepatri Heritage.
  • 23andMe: Largest global DTC genetic testing company offering ancestry and health predisposition reports. Mapmygenome accepts raw data uploads from 23andMe and competes for the same Indian wellness customer, though 23andMe lacks India-specific PRS calibration.
  • Ancestry: Global leader in ancestry DNA testing with the largest consumer genetic database. Mapmygenome competes for ancestry-driven Indian customers through Genomepatri Heritage, where its India-specific subpopulation database is a key differentiator.

Regional players

  • Prenetics: Hong Kong-listed genomics and preventive health company offering DNA testing, NIPT, and consumer health products across Asia. Regional competitor with comparable multi-omics ambitions and a Hong Kong/SEA geographic focus.
  • Circle DNA: Asia-focused (Hong Kong) premium genetic testing brand offering whole genome sequencing and health reports. Operates in the same premium-APAC wellness segment as Mapmygenome's international storefront but is primarily Greater China/Southeast Asia focused.

Direct peers

  • MedGenome: India-headquartered genomics and molecular diagnostics company offering genetic testing, NIPT, hereditary cancer panels, and clinical interpretation. Direct competitor in the Indian genetic diagnostics market across both DTC and clinical channels.
  • Strand Life Sciences: India-based clinical genomics and bioinformatics company providing genetic testing, NIPT, prenatal screening, and oncology panels. Competes head-to-head with Mapmygenome in India for clinical genomic testing services.
  • Xcode Life: Chennai-based DTC genetic testing company focused on South Asian consumers, offering nutrigenomics, fitness, and ancestry tests. Direct competitor in the Indian DTC wellness genomics niche with overlapping product positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Mapmygenome social profiles

Digital presence

Mapmygenome compliance and trust

Trust signal

Compliance9 records

Mapmygenome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mapmygenome leadership team

Management profile

Number of profiles

Profiles13 records

Mapmygenome subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mapmygenome funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mapmygenome M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mapmygenome

What does Mapmygenome do?

Mapmygenome offers direct-to-consumer at-home DNA testing kits (e.g., Genomepatri, MapmyBiome) and clinical diagnostic genomic tests (e.g., NIPT, Hereditary Cancer Panel, Whole Exome/Genome Sequencing) ordered through healthcare providers. The company provides end-to-end services including sample collection, multi-omics analysis (genomics, microbiome, epigenomics), polygenic risk score reporting, and genetic counseling.

Is Mapmygenome a public or private company?

Mapmygenome is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Mapmygenome founded?

Mapmygenome was founded in 2013. It employs 11 to 50 people.

Where is Mapmygenome based?

Mapmygenome is headquartered in Hyderabad, India, in the Asia region.

How does Mapmygenome make money?

Three revenue lines are on record. At-Home DNA Testing Kits are the primary driver. The others are premium Bundles and Programs and diagnostic Genomic Tests.

Who are Mapmygenome's main competitors?

Emerging players on record are Color Genomics and Nebula Genomics. Broad incumbents are MyHeritage, 23andMe and Ancestry. Regional players are Prenetics and Circle DNA. Direct peers are MedGenome, Strand Life Sciences and Xcode Life.

Does Mapmygenome have an API?

No public API is recorded for Mapmygenome.

What industry is Mapmygenome in?

Mapmygenome's product category is Genomic Testing Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMicrobiome Sequencing Service Market Report 2025The microbiome sequencing service market is projected to grow from $2.07 billion in 2024 to $2.43 billion in 2025, and reach $4.54 billion by 2029, driven by rising precision nutrition focus, microbiome-based therapeutics demand, and preventive healthcare awareness. MGI Tech Co. Ltd. launched its Human Microbiome Metagenomics Sequencing Package in July 2024, while Mapmygenome India Limited acquired Microbiome Insights Inc. in May 2025 to expand its sequencing capabilities and North American market presence. The market faces headwinds from global trade tensions and tariffs affecting healthcare sector costs and supply chains.DromicseduDr. Omics Education;The article identifies bioinformatics as the central discipline driving innovation in biotechnology for 2025, highlighting its critical role in genomics, drug discovery, and precision medicine. It outlines a strong career outlook driven by the integration of AI and machine learning, with specific growth noted in India through government initiatives and private sector expansion. Key industry players mentioned include Mapmygenome, Strand Life Sciences, and MedGenome, which are actively integrating these computational tools into clinical practice.The Times of IndiaMapmygenome acquires Canadian CRO Microbiome InsightsMapmygenome acquired Canadian microbial sequencing firm Microbiome Insights, including its CAP-accredited Canadian laboratory and intellectual property. The deal gives Mapmygenome 100% stake and aims to expand its North American footprint ahead of its Indian stock exchange listing later this year.PR NewswireMapmygenome cements global leadership in Genomics with strategic acquisition of Canada's Microbiome InsightsMapmygenome acquired Microbiome Insights, a global microbiome sequencing leader, including its CAP-accredited Canadian lab and IP. The deal expands Mapmygenome's North American presence with integrated genomics and microbiome testing. Financial terms were not disclosed.MapmygenomeTop 10 Fitness Trends of 2024: Optimize Your Health with Genetic Insights | MapmyGenomeMapmyGenome India Ltd outlines the top fitness trends for 2024, emphasizing personalized health plans and genetic-based nutrition derived from its Myfitgene testing services. The article highlights the integration of wearable technology with AI tools, specifically mentioning a partnership between Humanity's AI Health Coach app and MapmyGenome data to enhance user wellness insights.PR NewswireDNAtix And Mapmygenome Partner To Advance Personalized Preventive MedicineDNAtix Ltd., a blockchain genetics company based in Tel Aviv, and Mapmygenome, a molecular diagnostics company based in Hyderabad, announced a strategic partnership on August 6, 2018 to advance personalized and preventive medicine using blockchain technology. Under the agreement, Mapmygenome will join DNAtix's growing genetic ecosystem, enabling users to access in-depth analysis of full genome sequences with blockchain-based security and anonymity. India is identified as a key market for DNAtix's blockchain-based genetic services, with the partnership aimed at expanding access to genomic services globally.Forbes India2018 W-Power Trailblazers: Anu Acharya hopes to save a million lives by decoding genetic makeupAnu Acharya, CEO of Hyderabad-based Mapmygenome India, is highlighted as a 2018 W-Power Trailblazer, having launched the personal genomics company in 2013 after founding Ocimum Biosolutions in 2000. The firm has processed over 10,000 samples via its saliva-based Genomepatri test and reported 84 percent CAGR, ending the year with ₹6 crore revenue and negative Ebitda.Forbes IndiaLife in the Time of Genetic Decoding - Part 2The author describes undergoing exome sequencing at Strand Life Sciences, which identified seven carrier mutations, including for night blindness, retinitis pigmentosa and occult macular dystrophy, plus a slightly higher risk of fungal nail infections. Strand does not provide disease predisposition reports except in rare cases. The piece notes companies like Xcode and MapMyGenome, and previews Part III on regulations and ethics.